Skip to content

Safety and efficacy of conservative management vs. endovascular treatment in basilar trunk dolichoectasia aneurysms (ECTA Study)

Safety and efficacy of conservative management vs. endovascular treatment in basilar trunk dolichoectasia aneurysms: a multi-center, prospective, observational study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075151
Enrollment
Unknown
Registered
2023-08-28
Start date
2023-01-18
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

basilar trunk dolichoectasia aneurysm(BTDA)

Interventions

Observational group:None

Sponsors

Xuanwu hospital, Capital Medical University, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old, regardless of gender; 2. Untreated and unruptured BTDA diagnosed by MRI, HR-MRI, CTA or DSA;(MRI, CTA or DSA indicated the diameter of the dialated segment of basilar artery was 1.5 time larger than the normal segment or the diameter of basilar artery >4.5mm; Meanwhile, the length of basilar artery measured by MRI, CTA or DSA >29.5mm or MRI, HR-MRI indicated the lateral displacement of basilar artery >10mm;); 3. The patient or their family member signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1Previous ruptured history of the BTDA; 2Previous endovascular or surgical treatment of the BTDA; 3Other cerebral vascular disorders such as cerebral arteriovenous malformation, dural arteriovenous fistula, moyamoya disease, cerebrovascular stenosis/occlusion, and so on that have significant influence on the prognosis; 4Other malignant disease resulting in life expectancy less than 1 year; 5Other condition that improper for enrollment confirmed by the study leader.

Design outcomes

Primary

MeasureTime frame
5-year BTDA related neurological adverse event;

Secondary

MeasureTime frame
6-month and 1-year BTDA related neurological adverse event;6-month,1-year, and 5-year clinical outcome;6-month,1-year, and 5-year radiological outcome;

Countries

China

Contacts

Public ContactChuan He

Xuanwu hospital, Capital Medical University, China

streamhe@163.com+86 136 0111 0236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026